Find the latest Tobira Therapeutics, Inc. (TBRA) stock quote, history, news and other vital information to help you with your stock trading and investing. High institutional ownership can be a signal of strong market trust in this company.There is not enough analysis data for Tobira Therapeutics.Sign-up to receive the latest news and ratings for TBRA and its competitors with MarketBeat's FREE daily newsletter.One share of TBRA stock can currently be purchased for approximately $42.09.View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Learn about financial terms, types of investments, trading strategies and more.In the past three months, Tobira Therapeutics insiders have not sold or bought any company stock.Looking for new stock ideas? In the past three months, Tobira Therapeutics insiders have not sold or bought any company stock. Export data to Excel for your own analysis.Tobira Therapeutics trades on the NASDAQ under the ticker symbol "TBRA. Percentage Held by Institutions. Securities registered pursuant to Section 12(b) of the Act: Common Stock, Par Value $0.001 Per Share; Common stock traded on the NASDAQ stock market. TBRA stock quote, chart and news. Tobira Therapeutics is a clinical-stage biopharmaceutical company developing and commercialising therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases. Free forex prices, toplists, indices and lots more. Get short term trading ideas from the MarketBeat Idea Engine. O n Tuesday, shares of Tobira Therapeutics Inc. TBRA skyrocketed, up over 720% in late-afternoon trading after the company announced it would be … Receive a free world-class investing education from MarketBeat. View which stocks are hot on social media with MarketBeat's trending stocks report.Only 6.20% of the stock of Tobira Therapeutics is held by insiders.
TBRA: Get the latest Tobira Therapeutics stock price and detailed information including TBRA news, historical charts and realtime prices. NEW YORK -- Shares of Tobira Therapeutics () are skyrocketing on heavy trading volume on Tuesday morning by over 700% to $39.24, after it was … Want to see which stocks are moving?
Get Tobira Therapeutics, Inc.'s stock price today. See what's happening in the market right now with MarketBeat's real-time news feed. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.Get daily stock ideas top-performing Wall Street analysts. Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. The transaction is expected to close at the end of this year."With this acquisition, Allergan will now have one of the strongest portfolios of development stage programs for the treatment of NASH, with Cenicriviroc as the cornerstone. View our full suite of financial calendars and market data tables, all for free.Learn everything you need to know about successful options trading with this three-part video course.Tobira Therapeutics does not have a long track record of dividend growth.Tobira Therapeutics has received 60.00% “outperform” votes from our community.Please log in to your account or sign up in order to add this asset to your watchlist.Tobira Therapeutics' mailing address is 701 Gateway Blvd Ste 200, SOUTH SAN FRANCISCO, CA 94080-7041, United States. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication.